uniQure Faces Class Action Lawsuit Amid Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 26 2026
0mins
Should l Buy QURE?
Source: Globenewswire
uniQure N.V. (NASDAQ: QURE) saw its stock price rise by 16.82% and reach a 5-day high despite the broader market decline, with the Nasdaq-100 down 0.93% and the S&P 500 down 0.89%.
The company is currently facing multiple class action lawsuits due to allegations of securities fraud related to its Huntington's disease treatment, AMT-130. Investors who purchased shares between September 24 and October 31, 2025, are encouraged to apply as lead plaintiffs by April 13, 2026. The lawsuits claim that uniQure misrepresented the FDA approval status of its pivotal study, leading to significant investor losses when the truth was revealed, particularly after a stock price drop of over 49% following negative FDA feedback.
These legal challenges could have serious implications for uniQure's market reputation and financing capabilities, as investor confidence continues to wane amid these allegations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 18.260
Low
33.00
Averages
49.88
High
70.00
Current: 18.260
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
H.C. Wainwright Optimistic on uniQure's Gene Therapy Prospects
- Regulatory Shift: H.C. Wainwright noted that the departure of Vinay Prasad, head of the FDA's division of vaccines and gene therapies, will 'reshape the regulatory calculus' for uniQure's Huntington's disease gene therapy AMT-130, potentially accelerating its approval process.
- Price Target Increase: Analysts at Chardan nearly doubled their price target for uniQure from $16 to $31 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance, particularly in light of Prasad's departure.
- Stock Price Surge: Following a 26% increase on Monday, uniQure's stock rose nearly 7% in pre-market trading on Tuesday, reflecting market optimism regarding its gene therapy, especially after positive analyst commentary.
- Investor Sentiment Recovery: Although uniQure's stock is down 25% year-to-date, it has risen 45% over the past 12 months, indicating a bullish sentiment among retail investors on social media, highlighting the market's focus on its gene therapy prospects.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, to participate in the securities class action lawsuit concerning stock transactions between September 24 and October 31, 2025, highlighting investor concerns over company transparency.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the anticipated FDA accelerated approval for its leading drug candidate AMT-130, leading to diminished investor confidence.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA's timeline for AMT-130's BLA submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting a pessimistic outlook on the company's future.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding their legal options and connecting with Kahn Swick & Foti, LLC law firm, demonstrating a commitment to supporting investor rights.
See More
uniQure Faces Unprecedented Federal Rebuke Amid Lawsuit
- Federal Officials Condemnation: On March 5, 2026, The Wall Street Journal reported that FDA officials criticized uniQure for flawed clinical data regarding its Huntington's disease gene therapy, which failed to meet approval standards, severely impacting the company's reputation and stock price.
- Stock Price Plunge: Since November 3, 2025, uniQure's stock has fallen nearly 84%, reflecting extreme investor pessimism about the company's future and exacerbating market concerns regarding its viability.
- Securities Class Action: uniQure is facing a securities class action lawsuit representing investors who purchased shares between September 24 and October 31, 2025, alleging the company misrepresented key study designs and failed to disclose critical interactions with the FDA, potentially leading to increased investor losses.
- FDA Meeting Reveals Truth: In a recent FDA meeting, uniQure acknowledged that the timeline for its Biologics License Application for AMT-130 is now uncertain, indicating significant misrepresentation in clinical trial data that could lead to further regulatory hurdles and a crisis of market trust.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V., concerning stock purchases made between September 24 and October 31, 2025, or risk losing their right to claim.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, a drop of over 49%, from $67.69 on October 31 to $34.29, significantly undermining investor confidence and market perception of the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which has severely impacted investor trust and may lead to substantial liability for the company.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, indicating the firm's commitment to seeking recoveries for economic losses stemming from corporate misconduct.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, which has shaken investor confidence.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission is unclear, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, allowing them to represent other investors in the legal proceedings and protect their rights effectively.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP offers free case evaluations and encourages investors to reach out for more information on their legal rights and potential recovery options, ensuring that investors incur no costs in the process.
See More
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
H.C. Wainwright Optimistic on uniQure's Gene Therapy Prospects
- Regulatory Shift: H.C. Wainwright noted that the departure of Vinay Prasad, head of the FDA's division of vaccines and gene therapies, will 'reshape the regulatory calculus' for uniQure's Huntington's disease gene therapy AMT-130, potentially accelerating its approval process.
- Price Target Increase: Analysts at Chardan nearly doubled their price target for uniQure from $16 to $31 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance, particularly in light of Prasad's departure.
- Stock Price Surge: Following a 26% increase on Monday, uniQure's stock rose nearly 7% in pre-market trading on Tuesday, reflecting market optimism regarding its gene therapy, especially after positive analyst commentary.
- Investor Sentiment Recovery: Although uniQure's stock is down 25% year-to-date, it has risen 45% over the past 12 months, indicating a bullish sentiment among retail investors on social media, highlighting the market's focus on its gene therapy prospects.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, to participate in the securities class action lawsuit concerning stock transactions between September 24 and October 31, 2025, highlighting investor concerns over company transparency.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the anticipated FDA accelerated approval for its leading drug candidate AMT-130, leading to diminished investor confidence.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA's timeline for AMT-130's BLA submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting a pessimistic outlook on the company's future.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding their legal options and connecting with Kahn Swick & Foti, LLC law firm, demonstrating a commitment to supporting investor rights.
See More
uniQure Faces Unprecedented Federal Rebuke Amid Lawsuit
- Federal Officials Condemnation: On March 5, 2026, The Wall Street Journal reported that FDA officials criticized uniQure for flawed clinical data regarding its Huntington's disease gene therapy, which failed to meet approval standards, severely impacting the company's reputation and stock price.
- Stock Price Plunge: Since November 3, 2025, uniQure's stock has fallen nearly 84%, reflecting extreme investor pessimism about the company's future and exacerbating market concerns regarding its viability.
- Securities Class Action: uniQure is facing a securities class action lawsuit representing investors who purchased shares between September 24 and October 31, 2025, alleging the company misrepresented key study designs and failed to disclose critical interactions with the FDA, potentially leading to increased investor losses.
- FDA Meeting Reveals Truth: In a recent FDA meeting, uniQure acknowledged that the timeline for its Biologics License Application for AMT-130 is now uncertain, indicating significant misrepresentation in clinical trial data that could lead to further regulatory hurdles and a crisis of market trust.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V., concerning stock purchases made between September 24 and October 31, 2025, or risk losing their right to claim.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, a drop of over 49%, from $67.69 on October 31 to $34.29, significantly undermining investor confidence and market perception of the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which has severely impacted investor trust and may lead to substantial liability for the company.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, indicating the firm's commitment to seeking recoveries for economic losses stemming from corporate misconduct.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, which has shaken investor confidence.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission is unclear, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, allowing them to represent other investors in the legal proceedings and protect their rights effectively.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP offers free case evaluations and encourages investors to reach out for more information on their legal rights and potential recovery options, ensuring that investors incur no costs in the process.
See More
